Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pasientsentrert kirurgisk prehabilitering (Prehab)

26. september 2026 oppdatert av: Matthew Mossanen, MD, MPH, Brigham and Women's Hospital

The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.

Studieoversikt

Detaljert beskrivelse

This research study is testing the efficacy of the prehabilitation study which is a set of investigational interventions and also tries to define the most appropriate and effective set type of interventions to use for further studies. "Investigational" means that the intervention is being studied. In this research study, the investigators hope to learn whether or not this combination of prehabilitation interventions has an impact on the recoverability of participants who will undergo cystectomy or bladder removal surgery. The 5 interventions that make up the prehabilitation study are:

  • Participant Interview (If one of the first ten participants)
  • Exercise Testing
  • Exercise Training
  • Nutritional Support
  • Clinical Assessment of Nutritional Status

Studietype

Intervensjonell

Registrering (Antatt)

25

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Brigham and Women's Hospital
        • Hovedetterforsker:
          • Matthew Mossanen, MD
        • Ta kontakt med:
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Dana Farber Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Matthew Mossanen, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patents must be candidates for all types of cystectomy surgery including urinary diversion via open or robotic approach.
  2. Patients between the ages 18 and 85 years
  3. American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4
  4. Ileal conduit or ileal neobladder urinary diversion
  5. Able to understand the study procedures, agreed to participate in the study program, and voluntarily provided informed consent

Exclusion Criteria:

  1. Scheduled for a partial cystectomy
  2. Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy
  3. More than three doses of opioids (oral or parenteral) within 7 days before the day of surgery
  4. The presence of metastatic cancer
  5. Be undergoing treatment for another type of cancer concurrently
  6. Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed.
  7. Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam; or abstinence) (Participants will be asked to use birth control for the entire study and for at least 2 weeks after the last dose of study drug.)
  8. Participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study
  9. Clinically significant laboratory abnormalities at screening that would have resulted in the cancellation of surgery
  10. Using illicit drugs or abusing alcohol
  11. History of previous surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might have confounded the study results or might have posed additional risk in administering the study procedures
  12. Patients with severe dementia (as determined from medical records and history. Severe dementia will be defined as dementia that impacts daily functioning.)
  13. Patients with severe hepatic impairment as defined by Child-Pugh Class C. Patients with Child-Pugh Class A-B hepatic impairment are eligible for the study.
  14. A history of heart failure.
  15. Patients with end-stage renal disease as defined by GFR <15.
  16. Patients with heart failure.
  17. Patients with complete gastrointestinal obstruction.
  18. Patients with gastrostomy tube, jejunostomy tube or who require enteral tube feeds.
  19. Non-English-speaking patients

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Standard treatment Plan

This is the main arm of the study in which all 25 anticipated participants will be enrolled into.

Virtually supervised exercise training for four weeks prior to cystectomy

Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total days hospitalized within 30-days of surgery
Tidsramme: 60 months

This is the total number of days within 30 days after bladder removal surgery, that a patient is hospitalized.

60 months
Length of stay
Tidsramme: 60 months

This is the total length of stay in days after bladder removal surgery

60 months
Number and type of minor and major complications
Tidsramme: 60 months

This is the number and types of major and minor complications which occur post bladder removal surgery

60 months
Discharge disposition
Tidsramme: 60 months

This is the disposition of the patient at discharge or when the patient is released from the hospital.

60 months
Readmissions
Tidsramme: 60 months

This is the number of times a patient that was discharged come back to the hospital for any issue related to their bladder removal surgery.

60 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mars 2023

Primær fullføring (Antatt)

27. desember 2026

Studiet fullført (Antatt)

25. desember 2027

Datoer for studieregistrering

Først innsendt

18. januar 2023

Først innsendt som oppfylte QC-kriteriene

27. januar 2023

Først lagt ut (Faktiske)

8. februar 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. september 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-delingstidsramme

Data can be shared no earlier than 1 year following the date of publication

Tilgangskriterier for IPD-deling

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere